MicroRNA‑195 as a diagnostic biomarker in human cancer detection: A meta‑analysis

Liu,Baoer; Liu,Yuhan; Luo,Xueying; Pan,Yue; Yang,Liping; Li,Feng; Gao,Rui; Chen,Weicai; He,Jinsong

doi:10.3892/ol.2018.9489

MicroRNA‑195 as a diagnostic biomarker in human cancer detection: A meta‑analysis

Authors:
- Baoer Liu
- Yuhan Liu
- Xueying Luo
- Yue Pan
- Liping Yang
- Feng Li
- Rui Gao
- Weicai Chen
- Jinsong He
View Affiliations

Affiliations: Department of Breast Surgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000, P.R. China, Department of Urology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000, P.R. China, Department of Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518000, P.R. China
Published online on: September 24, 2018 https://doi.org/10.3892/ol.2018.9489
Pages: 6253-6260
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) show great promise as novel cancer biomarkers. Several studies have revealed an association between abnormal miRNA expression and the risk of various cancer types. However, the diagnostic accuracy and reliability of miRNAs remains unclear. The present meta‑analysis was performed to summarize the overall diagnostic performance of miR‑195 for cancer. The PubMed, Cochrane Library, Wanfang and China National Knowledge Infrastructure databases were searched for associated literature published until December 10, 2017. Eligible studies were selected using multiple search strategies based on study selection criteria. Measures, including sensitivity and specificity, of the performance of miR‑195 as a cancer diagnostic tool were pooled using bivariate meta‑analysis models. All analyses were performed using Stata 14.0. The pooled analysis included 8 studies comprising 735 cases and 547 controls. The pooled diagnostic results calculated from all studies were as follows: Sensitivity, 0.79 [95% confidence interval (CI), 0.69‑0.87]; specificity, 0.84 (95% CI, 0.68‑0.93); positive likelihood ratio, 4.9 (95% CI, 2.50‑9.50); negative likelihood ratio, 0.25 (95% CI, 0.18‑0.35); diagnostic odds ratio, 20 (95% CI, 10.00‑38.00); and area under the curve, 0.87 (95% CI, 0.84‑0.90). Deeks' funnel plot asymmetry test suggested no potential publication bias (P=0.53). The present meta‑analysis indicated that miR‑195 could be a reliable non‑invasive biomarker for the diagnosis of cancer. Further large‑scale prospective studies are necessary to confirm the present findings and the clinical value of miR‑195 for future diagnostics.

View Figures

View References

1	Bray F, Ren JS, Masuyer E and Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Shin VY and Chu KM: MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
5	Hainaut P and Plymoth A: Targeting the hallmarks of cancer: Towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 25:50–51. 2013. View Article : Google Scholar : PubMed/NCBI
6	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bartels CL and Tsongalis GJ: MicroRNAs: Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009. View Article : Google Scholar : PubMed/NCBI
8	Fabbri M: miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn. 10:435–444. 2010. View Article : Google Scholar : PubMed/NCBI
9	Madhavan D, Cuk K, Burwinkel B and Yang R: Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 4:1162013. View Article : Google Scholar : PubMed/NCBI
10	Weiland M, Gao XH, Zhou L and Mi QS: Small RNAs have a large impact: Circulating microRNAs as biomarkers for human diseases. RNA Biol. 9:850–859. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zen K and Zhang CY: Circulating microRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 32:326–348. 2012. View Article : Google Scholar : PubMed/NCBI
12	Su K, Zhang T, Wang Y and Hao G: Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer. World J Surg Oncol. 14:2242016. View Article : Google Scholar : PubMed/NCBI
13	Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M and Enokida H: The microRNA expression signature of bladder cancer by deep sequencing: The functional significance of the miR-195/497 cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
14	Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu Z, Liu T and Hu F: miR-195 is a key regulator of Raf1 in thyroid cancer. Onco Targets Ther. 8:3021–3028. 2015. View Article : Google Scholar : PubMed/NCBI
16	Yang B, Tan Z and Song Y: Study on the molecular regulatory mechanism of MicroRNA-195 in the invasion and metastasis of colorectal carcinoma. Int J Clin Exp Med. 8:3793–3800. 2015.PubMed/NCBI
17	Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
18	Li Z, Wang H, Wang Z and Cai H: MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1. Tumour Biol. 37:6457–6463. 2016. View Article : Google Scholar : PubMed/NCBI
19	Wang M, Zhang J, Tong L, Ma X and Qiu X: MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA. Int J Clin Exp Pathol. 8:14110–14120. 2015.PubMed/NCBI
20	Susluer Yilaz S, Avci Biray C, Dodurga Y, Ozlem Dogan Sigva Z, Oktar N and Gunduz C: Downregulation of miR-195 via cyclosporin A in human glioblastoma cells. J BUON. 20:1337–1340. 2015.PubMed/NCBI
21	Jia LF, Wei SB, Gong K, Gan YH and Yu GY: Prognostic implications of micoRNA miR-195 expression in human tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
22	Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu H, Xiao B, Jiao CH, Tang NN, Ma JJ, et al: Differential expression of miR-195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. FEBS Lett. 587:3471–3479. 2013. View Article : Google Scholar : PubMed/NCBI
23	Han K, Chen X, Bian N, Ma B, Yang T, Cai C, Fan Q, Zhou Y and Zhao TB: MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1. Oncotarget. 6:8875–8889. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhu Y, Wang EL, Li H, Zhong CC, Liu JN and Duan GK: Clinical significance of serum miR-195 in the diagnosis of breast cancer. J Tropical Med. 13:833–836. 2013.
25	Heneghan HM, Miller N, Kelly R, Newell J and Kerin MJ: Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 15:673–682. 2010. View Article : Google Scholar : PubMed/NCBI
26	Motawi TK, Shaker OG, El-Maraghy SA and Senousy MA: Serum MicroRNAs as potential biomarkers for early diagnosis of hepatitis C virus-related hepatocellular carcinoma in Egyptian patients. PLoS One. 10:e01377062015. View Article : Google Scholar : PubMed/NCBI
27	Yang IP, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH and Wang JY: Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. J Transl Med. 14:1082016. View Article : Google Scholar : PubMed/NCBI
28	Zhang WZ, Li Y and Tao CH: Value of combined detection of multiple miRNA in diagnosis of early breast carcinoma. J Hainan Med Univ. 22:1591–1593. 2016.
29	Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG, Ge SL and Zhang YK: Serum microRNA-195 is down-regulated in breast cancer: A potential marker for the diagnosis of breast cancer. Mol Biol Rep. 41:5913–5922. 2014. View Article : Google Scholar : PubMed/NCBI
30	Leeflang MM: Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect. 20:105–113. 2014. View Article : Google Scholar : PubMed/NCBI
31	Vamvakas EC: Meta-analyses of studies of the diagnostic accuracy of laboratory tests: A review of the concepts and methods. Arch Pathol Lab Med. 122:675–686. 1998.PubMed/NCBI
32	Rutter CM and Gatsonis CA: A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 20:2865–2884. 2001. View Article : Google Scholar : PubMed/NCBI
33	Deeks JJ, Macaskill P and Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 58:882–893. 2005. View Article : Google Scholar : PubMed/NCBI
34	Hong Z, Zhang R and Qi H: Diagnostic and prognostic relevance of serum miR-195 in pediatric acute myeloid leukemia. Cancer Biomark. 21:269–275. 2018. View Article : Google Scholar : PubMed/NCBI
35	Paranjape T, Slack FJ and Weidhaas JB: MicroRNAs: Tools for cancer diagnostics. Gut. 58:1546–1554. 2009. View Article : Google Scholar : PubMed/NCBI
36	Lu J, Xie F, Geng L, Shen W, Sui C and Yang J: Potential role of MicroRNA-210 as biomarker in human cancers detection: A Meta-analysis. Biomed Res Int. 2015:3039872015. View Article : Google Scholar : PubMed/NCBI
37	Lu D, Luo P, Wang Q, Ye Y and Wang B: lncRNA PVT1 in cancer: A review and meta-analysis. Clin Chim Acta. 474:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
38	Shuai P, Zhou Y, Gong B, Jiang Z, Yang C, Yang H, Zhang D and Zhu S: Long noncoding RNA MALAT1 can serve as a valuable biomarker for prognosis and lymph node metastasis in various cancers: A meta-analysis. Springerplus. 5:17212016. View Article : Google Scholar : PubMed/NCBI